Karyopharm Therapeutics Inc. (KPTIQ) bonds
Price, market cap and P/E appear here once daily prices are connected.
Debt
Borrowings on the balance sheet, Jun 30, 2026
Karyopharm Therapeutics reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2021
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Karyopharm Therapeutics's 10-Q for the period ended Jun 30, 2026
| Issue | Matures | Amount issued | Carrying value |
|---|---|---|---|
| Amended Term Loan | May 31, 2028 | $128.98M | $153.64M |
| Two Thousand Twenty Eight Notes Convertible at $7 a share | Oct 15, 2028 | $15.65M | $19.24M |
| New Two Thousand Twenty Nine Notes | May 13, 2029 | $107.97M | $138.27M |
| New Two Thousand Twenty Nine Notes And Two Thousand Twenty Nine Notes | – | $105.60M | $89.97M |
| Six Percentage Secured Convertible Senior Notes Due Two Thousand Twenty Nine Convertible | – | $111.00M | – |
| Two Thousand Twenty Nine Notes | – | $0 | – |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size |
|---|---|
| Credit Agreement And Term Loan | $100.00M |
See a number that looks wrong?